{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:05:19Z","timestamp":1791939919677,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005481","name":"School of Medicine, New York University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005481","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178047","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:08:40Z","timestamp":1754579320000},"page":"178047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD \u2013 A phase 2A clinical trial"],"prefix":"10.1016","volume":"1005","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-7712","authenticated-orcid":false,"given":"Daniel P.","family":"Radin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178047_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.psc.2003.12.003","article-title":"Diagnosis and evaluation of adults with attention-deficit\/hyperactivity disorder","volume":"27","author":"Adler","year":"2004","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.ejphar.2025.178047_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.biopsych.2012.05.012","article-title":"A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit\/hyperactivity disorder","volume":"72","author":"Adler","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.58.4.802","article-title":"Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466","volume":"58","author":"Arai","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178047_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/jpet.102.040360","article-title":"Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action","volume":"303","author":"Arai","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178047_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.24272\/j.issn.2095-8137.2022.122","article-title":"Deficiency of transmembrane AMPA receptor regulatory protein gamma-8 leads to attention-deficit hyperactivity disorder-like behavior in mice","volume":"43","author":"Bai","year":"2022","journal-title":"Zool. Res."},{"key":"10.1016\/j.ejphar.2025.178047_bib6","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1176\/ajp.2006.163.10.1730","article-title":"Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder","volume":"163","author":"Biederman","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.178047_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1176\/appi.ajp.2007.07030419","article-title":"Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders","volume":"165","author":"Biederman","year":"2008","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.178047_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0269881111405353","article-title":"Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep","volume":"26","author":"Boyle","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2025.178047_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2025.178047_bib10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/npp.2017.30","article-title":"Disrupted glutamatergic transmission in prefrontal cortex contributes to behavioral abnormality in an animal model of ADHD","volume":"42","author":"Cheng","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2025.178047_bib11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/npp.2013.349","article-title":"Amphetamine-induced dopamine release and neurocognitive function in treatment-naive adults with ADHD","volume":"39","author":"Cherkasova","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2025.178047_bib12","first-page":"175","article-title":"Conners' continuous performance test II (CPT II v. 5)","volume":"29","author":"Conners","year":"2000","journal-title":"Multi-Health Syst. Inc."},{"key":"10.1016\/j.ejphar.2025.178047_bib13","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/jclp.20122","article-title":"Pharmacotherapy of adult ADHD","volume":"61","author":"Dodson","year":"2005","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.ejphar.2025.178047_bib15","series-title":"ADHD Rating Scale\u2014Iv: Checklists, Norms, and Clinical Interpretation","author":"DuPaul","year":"1998"},{"key":"10.1016\/j.ejphar.2025.178047_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1744-9081-1-16","article-title":"Efficacy of atomoxetine in adult attention-deficit\/hyperactivity disorder: a drug-placebo response curve analysis","volume":"1","author":"Faraone","year":"2005","journal-title":"Behav. Brain Funct."},{"key":"10.1016\/j.ejphar.2025.178047_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1037\/h0025911","article-title":"Creative functioning and cognitive regression","volume":"9","author":"Gamble","year":"1968","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.ejphar.2025.178047_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00148581-200911030-00005","article-title":"Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents","volume":"11","author":"Garnock-Jones","year":"2009","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ejphar.2025.178047_bib19","series-title":"Rev Ed. U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration","article-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.ejphar.2025.178047_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.ejphar.2025.178047_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00213-008-1360-z","article-title":"Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman Primates by the ampakine CX717","volume":"202","author":"Hampson","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2025.178047_bib23","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12979","article-title":"Efficacy and safety of guanfacine extended-release in the treatment of attention-Deficit\/Hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study","volume":"81","author":"Iwanami","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12888-020-02867-8","article-title":"Safety and efficacy of guanfacine extended-release in adults with attention-deficit\/hyperactivity disorder: an open-label, long-term, phase 3 extension study","volume":"20","author":"Iwanami","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib25","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1037\/0022-0663.67.6.882","article-title":"Forward and backward digit span interaction with race and IQ: predictions from Jensen's theory","volume":"67","author":"Jensen","year":"1975","journal-title":"J. Educ. Psychol."},{"key":"10.1016\/j.ejphar.2025.178047_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"10.1016\/j.ejphar.2025.178047_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1017\/S0033291704002892","article-title":"The world health organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ejphar.2025.178047_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","article-title":"The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication","volume":"163","author":"Kessler","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.178047_bib29","first-page":"107","article-title":"Treatment of adults with attention-deficit\/hyperactivity disorder","volume":"4","author":"Kolar","year":"2008","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejphar.2025.178047_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.brainres.2010.07.088","article-title":"Cyclothiazide induces seizure behavior in freely moving rats","volume":"1355","author":"Kong","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2025.178047_bib31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.tins.2006.07.007","article-title":"Ampakines and the threefold path to cognitive enhancement","volume":"29","author":"Lynch","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2025.178047_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2014.11","article-title":"Glutamate\/glutamine and neuronal integrity in adults with ADHD: a proton MRS study","volume":"4","author":"Maltezos","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00023210-200620030-00001","article-title":"Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders","volume":"20","author":"Marenco","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2025.178047_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","article-title":"Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies","volume":"53","author":"Michelson","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib35","first-page":"571","article-title":"Recent advances in positive allosteric modulators of the AMPA receptor","volume":"9","author":"Morrow","year":"2006","journal-title":"Curr. Opin. Drug Discov. Dev"},{"key":"10.1016\/j.ejphar.2025.178047_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.acn.2004.02.004","article-title":"Test review-Comprehensive trail making test (CTMT)","volume":"19","author":"Moses","year":"2004","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.ejphar.2025.178047_bib37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","article-title":"A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-Deficit\/Hyperactivity disorder","volume":"36","author":"Nasser","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2025.178047_bib38","first-page":"181","article-title":"AMPA receptor potentiators for the treatment of CNS disorders","volume":"3","author":"O'Neill","year":"2004","journal-title":"Curr. Drug Targets: CNS Neurol. Disord."},{"key":"10.1016\/j.ejphar.2025.178047_bib39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/clpt.2009.194","article-title":"Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia","volume":"87","author":"Oertel","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.178047_bib40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jpsychires.2006.12.007","article-title":"Reduced cingulate glutamate\/glutamine-to-creatine ratios in adult patients with attention deficit\/hyperactivity disorder -- a magnet resonance spectroscopy study","volume":"41","author":"Perlov","year":"2007","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2025.178047_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030299","article-title":"Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates","volume":"3","author":"Porrino","year":"2005","journal-title":"PLoS Biol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.178047_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22310","article-title":"High impact AMPAkines induce a Gq-protein coupled endoplasmic calcium release in cortical neurons: a possible mechanism for explaining the toxicity of high impact AMPAkines","volume":"78","author":"Radin","year":"2024","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2025.178047_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177317","article-title":"Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy Male subjects and elderly healthy Male and female subjects","author":"Radin","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178047_bib44","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/neuroglia5030023","article-title":"High-impact AMPAkines elevate calcium levels in cortical astrocytes by mobilizing endoplasmic reticular calcium stores","volume":"5","author":"Radin","year":"2024","journal-title":"Neuroglia"},{"key":"10.1016\/j.ejphar.2025.178047_bib45","article-title":"Safety, tolerability, and pharmacokinetic profile of the low-impact ampakine CX1739 in young healthy volunteers","author":"Radin","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.ejphar.2025.178047_bib46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.biopha.2018.06.008","article-title":"Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain","volume":"105","author":"Radin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2025.178047_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/futurepharmacol4010012","article-title":"Low-impact ampakine CX1739 exerts pro-cognitive effects and reverses opiate-induced respiratory depression in rodents","volume":"4","author":"Radin","year":"2024","journal-title":"Future Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178047_bib48","first-page":"1","article-title":"Preclinical characterization of a water-soluble low-impact ampakine prodrug, CX1942 and its active moiety, CX1763","author":"Radin","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178047_bib49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/futurepharmacol4030028","article-title":"Preclinical pharmacology of the low-impact ampakine CX717","volume":"4","author":"Radin","year":"2024","journal-title":"Future Pharmacol."},{"key":"10.1016\/j.ejphar.2025.178047_bib51","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/ALN.0b013e31819faa2a","article-title":"Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats","volume":"110","author":"Ren","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2025.178047_bib52","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1152\/japplphysiol.00752.2012","article-title":"Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717","volume":"113","author":"Ren","year":"2012","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.ejphar.2025.178047_bib53","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/ALN.0b013e318291079c","article-title":"Coadministration of the AMPAKINE CX717 with propofol reduces respiratory depression and fatal apneas","volume":"118","author":"Ren","year":"2013","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2025.178047_bib54","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14379","article-title":"Young-adult social outcomes of attention-Deficit\/Hyperactivity disorder","volume":"84","author":"Riglin","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib55","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14379","article-title":"Investigating young-adult social outcomes of attention deficit hyperactivity disorder","volume":"84","author":"Riglin","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/jpet.113.204735","article-title":"Positive allosteric modulation of AMPA receptors from efficacy to toxicity: the interspecies exposure-response continuum of the novel potentiator PF-4778574","volume":"347","author":"Shaffer","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.178047_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","article-title":"Variable patterns of remission from ADHD in the multimodal treatment study of ADHD","volume":"179","author":"Sibley","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.178047_bib58","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.biopsych.2004.11.043","article-title":"A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit\/hyperactivity disorder","volume":"57","author":"Spencer","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib59","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/archpsyc.58.8.775","article-title":"Efficacy of a mixed amphetamine salts compound in adults with attention-deficit\/hyperactivity disorder","volume":"58","author":"Spencer","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ambp.2006.07.006","article-title":"Attention-Deficit\/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology","volume":"7","author":"Spencer","year":"2007","journal-title":"Ambul. Pediatr."},{"key":"10.1016\/j.ejphar.2025.178047_bib61","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/jcpp.12684","article-title":"Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit\/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression","volume":"58","author":"Swanson","year":"2017","journal-title":"J Child Psychol Psychiatry"},{"key":"10.1016\/j.ejphar.2025.178047_bib62","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0028-3908(01)00031-4","article-title":"Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo","volume":"40","author":"Vandergriff","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2025.178047_bib63","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3357\/ASEM.2055.2007","article-title":"Ampakine (CX717) effects on performance and alertness during simulated night shift work","volume":"78","author":"Wesensten","year":"2007","journal-title":"Aviat Space Environ. Med."},{"key":"10.1016\/j.ejphar.2025.178047_bib64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1196\/annals.1300.015","article-title":"Mechanisms by which dopamine receptors May influence synaptic plasticity","volume":"1003","author":"Wolf","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2025.178047_bib65","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.4155\/fmc-2020-0256","article-title":"The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats","volume":"12","author":"Xiao","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejphar.2025.178047_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/aps.2017.138","article-title":"Prefrontal AMPA receptors are involved in the effect of methylphenidate on response inhibition in rats","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2025.178047_bib67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/156720511798192709","article-title":"Effects of the putative cognitive-enhancing ampakine, CX717, on attention and object recognition memory","volume":"8","author":"Zheng","year":"2011","journal-title":"Curr. Alzheimer Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:37:54Z","timestamp":1762144674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":66,"alternative-id":["S0014299925008015"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178047","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD \u2013 A phase 2A clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178047"}}